Peer-reviewed veterinary case report
Doxorubicin and deracoxib after spleen removal for dog cancer survival
By Kahn, S Anthony et al.·Published in The Canadian veterinary journal = La revue veterinaire canadienne·2013·Centre Vé, Canada·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Doxorubicin and deracoxib adjuvant therapy for canine splenic hemangiosarcoma: a pilot study.
- Species:
- dog
Plain-English summary
A group of dogs with splenic hemangiosarcoma, a serious type of tumor, received a combination of two treatments: doxorubicin (a common chemotherapy drug) and deracoxib (a Cox-2 inhibitor). This treatment was given after the dogs had surgery to remove the spleen. The dogs tolerated the combination well, with only mild side effects like stomach upset and low blood cell counts. On average, the dogs lived about 150 days after starting treatment, which is a promising outcome for those with this aggressive cancer. More research is needed to see how effective Cox-2 inhibitors can be for dogs with this condition.
People also search for: dog hemangiosarcoma treatment · doxorubicin side effects in dogs · deracoxib for dog cancer
Abstract
Canine hemangiosarcoma (HSA) is a highly malignant tumor for which standard chemotherapy has done little to substantially improve survival. Cyclooxygenase-2 (Cox-2) plays a role in the formation, growth, and metastasis of tumors and inhibitors have demonstrated therapeutic benefit with certain canine cancers. In this prospective study, 21 dogs received adjuvant therapy combining the selective Cox-2 inhibitor deracoxib with doxorubicin, following splenectomy for HSA. The combination was well-tolerated with only low-grade gastrointestinal and hematologic toxicities noted. An overall median survival of 150 days (range; 21 to 1506 days) was noted. Although there was no significant difference in survival based upon stage of disease, dogs with stage III HSA (n = 11) had a median survival of 149 days, which appears to be longer than previously reported. Further studies are warranted to evaluate the potential benefit of Cox-2 inhibitors in the treatment of canine HSA.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/23997259/